Real-world evaluation of early remdesivir in high-risk COVID-19 outpatients during Omicron including BQ.1/BQ.1.1/XBB.1.5.

Publication date: Aug 08, 2024

A trial performed among unvaccinated, high-risk outpatients with COVID-19 during the delta period showed remdesivir reduced hospitalization. We used our real-world data platform to determine the effectiveness of remdesivir on reducing 28-day hospitalization among outpatients with mild-moderate COVID-19 during an Omicron period including BQ. 1/BQ. 1.1/XBB. 1.5. We did a propensity-matched, retrospective cohort study of non-hospitalized adults with SARS-CoV-2 infection between April 7, 2022, and February 7, 2023. Electronic healthcare record data from a large health system in Colorado were linked to statewide vaccination and mortality data. We included patients with a positive SARS-CoV-2 test or outpatient remdesivir administration. Exclusion criteria were other SARS-CoV-2 treatments or positive SARS-CoV-2 test more than seven days before remdesivir. The primary outcome was all-cause hospitalization up to day 28. Secondary outcomes included 28-day COVID-related hospitalization and 28-day all-cause mortality. Among 29,270 patients with SARS-CoV-2 infection, 1,252 remdesivir-treated patients were matched to 2,499 untreated patients. Remdesivir was associated with lower 28-day all-cause hospitalization (1. 3% vs. 3. 3%, adjusted hazard ratio (aHR) 0. 39 [95% CI 0. 23-0. 67], p 

Open Access PDF

Concepts Keywords
Colorado COVID-19
February Nonhospitalized
Outpatient Omicron variant
Outpatient
Remdesivir
SARS-CoV-2
Veklury

Semantics

Type Source Name
disease MESH COVID-19
disease VO unvaccinated
disease VO effectiveness
pathway REACTOME SARS-CoV-2 Infection
disease VO vaccination
disease MESH Infectious Diseases
disease IDO symptom
disease MESH death
drug DRUGBANK Ritonavir
disease VO population
disease VO immunization
disease MESH emergency
disease VO ineffective
disease MESH comorbidity
drug DRUGBANK Trestolone
drug DRUGBANK Pentaerythritol tetranitrate
disease MESH treatment failure
disease MESH obesity
disease MESH hypertension
disease MESH cardiovascular disease
disease MESH diabetes mellitus
disease MESH pulmonary disease
drug DRUGBANK Oxygen
drug DRUGBANK Isoxaflutole
disease VO dose
disease VO time
disease IDO process
disease VO age
disease MESH Liver Disease
disease VO vaccinated
disease IDO healthcare facility
disease MESH drug interactions
disease VO publication
disease VO USA
disease VO injection
drug DRUGBANK Coenzyme M
disease VO report
disease VO VacA
disease MESH contraindications

Original Article

(Visited 1 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *